Skip to main content

Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders

Buy Article:

$51.00 plus tax (Refund Policy)


Kopala L, Smith G, Malla A, Williams R, Love L, Talling D, Balshaw R. Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.

Acta Psychiatr Scand 2006: 113 (Suppl. 430): 29–39. © 2006 Blackwell Munksgaard. Objective: 

To determine how the use of the newer, so called atypical antipsychotic medications, effects the pharmacoeconomic treatment burden of schizophrenia and related conditions and to provide a clear comparison of the costs and risks associated with these atypical drugs. Method: 

In this 2-year, open-label, prospective study, resource utilization (RU) data were collected on 160 patients with these conditions. A comparison between risks and costs was performed by combining the generalized CNOMSS data on both economic factors and risk assessments. Results: 

The main findings of the study were that the total adjusted 1- and 2-year costs were lowest for quetiapine. Drug acquisition costs were lowest for risperidone for both the 1- and 2-year cohorts. Clozapine use was predictably associated with the highest overall and medication costs at both 1 and 2 years. Conclusion: 

Treatment with risperidone or quetiapine was associated with the lowest overall costs when compared with olanzapine or clozapine.

Keywords: cost analysis; prognosis; schizophrenia

Document Type: Research Article


Affiliations: 1: Department of Psychiatry, University of British Columbia, Vancouver, BC 2: Department of Psychiatry, McGill University, Montreal, QC 3: Syreon Corporation, Vancouver, BC, Canada

Publication date: 2006-05-01

  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more